The Merck & Co and Roche-backed Duchenne muscular dystrophy drug developer has gone public in an upsized IPO sized at approximately $182m.

US-based drug delivery platform developer Entrada Therapeutics raised almost $182m on Friday in an initial public offering that marks an exit for pharmaceutical firms Merck & Co and Roche.

The offering involved the sale of just over 9 million shares, priced at $20.00 each on the Nasdaq Global Market. It was upsized from 7.5 million shares which were priced at the middle of its $19 to $21 range.

Entrada has developed endosomal escape vehicle (EEV) technology that precisely delivers medication to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
email
Linked in